Safety of recombinant and plasma-derived medicinals for the treatment of coagulopathies.
The introduction of advanced technologies (PCR testing, chromatography, and specific viral inactivation and removal techniques) has led to remarkable improvements in the quality and efficacy of biopharmaceutical products. The current safety strategies for both recombinant protein and PDP products depend on the extensive screening of the source material for infectious agents and the use of mild purification methods, specific mild viral-reduction techniques, GMP, QC, and QA. An appropriate system of pharmacologic vigilance is also an integral element for assuring product quality and safety in the marketplace. Such precautions make available high quality therapeutic recombinant proteins and PDP products. The risks in the clinical setting and the cost/benefit ratio must be considered in choosing a product for therapeutic use. The choice should be based on the analysis of data available for a specific product, because some variations in quality and safety can be observed in different brands. Overall, a much finer control of infectious risks has been achieved, and improvement will continue. With the new products, thrombotic episodes have become rare. Reducing immunogenic potential and improving yield to increase product supply could be the next challenges for producers of biopharmaceuticals.
Radosevich
M
M
Research and Development-Business Development, Human Plasma Product Services, Lille, France. radosev@attglobal.net
D000818:Animals; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D006801:Humans; D010949:Plasma; D011328:Prions; D011786:Quality Control; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012449:Safety; D014777:Virus Diseases / Q000635:transmission
D001779:Blood Coagulation Factors; D011328:Prions; D011994:Recombinant Proteins